ヨシナガ　ケンタロウ   Yoshinaga Kentarou   吉永　健太郎    所属   医学部 医学科（東京女子医科大学病院）    職種   講師
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	High PRAME expression is associated with poor survival and early disease progression in myelodysplastic syndromes with a low bone marrow blast percentage.
掲載誌名	正式名：Leukemia & lymphoma 略　 称：Leuk Lymphoma ISSNコード：10292403/10268022
掲載区分	国外
巻・号・頁	62(10),pp.2448-2456
著者・共著者	Shiseki Masayuki†*, Ishii Mayuko, Ohwashi Mari, Wang Yan-Hua, Tanaka Norina, Osanai Satoko, Yoshinaga Kentaro, Mori Naoki, Tanaka Junji
発行年月	2021/10
概要	We investigated the clinical implications of preferentially expressed antigen in melanoma (PRAME) expression in bone marrow cells of 116 patients with myelodysplastic syndromes (MDS). Quantitative RT-PCR was carried out to examine the PRAME expression level. High PRAME expression was observed in MDS patients classified into higher revised International Prognostic Scoring System (IPSS-R) risk categories (Very high and High) with a high bone marrow blast percentage (5% or higher). Kaplan-Meier analysis demonstrated that high PRAME expression is significantly associated with a poorer overall survival (OS) in MDS patients with a low bone marrow blast percentage (less than 5%) (log-rank test p = .0014) and those classified into lower IPSS-R risk categories (Very Low, Low, and Intermediate) (log-rank test, p = .0035). In contrast, there was no significant association between PRAME expression and OS in MDS patients with a high bone marrow blast percentage or those classified into higher IPSS-R risk categories. In addition, high PRAME expression was associated with early disease progression in MDS patients with a low bone marrow blast percentage. This study suggested PRAME expression to be a prognostic factor in MDS.
DOI	10.1080/10428194.2021.1919659
PMID	34013846